Please use this identifier to cite or link to this item:
|Title:||RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status|
|Citation:||Omar, M.F.M., Ito, K., Nga, M.E., Soo, R., Peh, B.K., Ismail, T.M., Thakkar, B., Soong, R., Ito, Y., Salto-Tellez, M. (2012-10). RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status. Pathology and Oncology Research 18 (4) : 783-792. ScholarBank@NUS Repository. https://doi.org/10.1007/s12253-011-9485-5|
|Abstract:||RUNX3 aberrations play a pivotal role in the oncogenesis of breast, gastric, colon, skin and lung tissues. The aim of this study was to characterize further the expression of RUNX3 in lung cancers. To achieve this, a lung cancer tissue microarray (TMA), frozen lung cancer tissues and lung cell lines were examined for RUNX3 expression by immunohistochemistry, while the TMAwas also examined for EGFR and p53 expression. RUNX3 promoter methylation status, and EGFR and KRAS mutation status were also investigated. Inactivation of RUNX3 was observed in 70% of the adenocarcinoma samples, and this was associated with promoter hypermethylation but not biased to EGFR/KRAS mutations. Our results suggest a central role of RUNX3 downregulation in pulmonary adenocarcinoma, which may not be dependent of other established cancer-causing pathways and may have important diagnostic and screening implications. © Arányi Lajos Foundation 2012.|
|Source Title:||Pathology and Oncology Research|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 17, 2019
WEB OF SCIENCETM
checked on Jan 1, 2019
checked on Jan 18, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.